title: The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women.
abstract: To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum.
  
  
  
  A nonrandomized, open-label, multicentre, phase-IV study.
  
  
  
  HIV-positive pregnant women receiving abacavir 600 mg q.d. as part of clinical care were included. Intensive 24-h pharmacokinetic sampling was performed during the third trimester and at least 2 weeks after delivery. Pharmacokinetic parameters were calculated by noncompartmental analysis. Paired cord blood and maternal blood samples were taken at delivery when feasible.
  
  
  
  A total of 14 women were included in the analysis. Geometric mean ratios (90% confidence intervals) of third trimester versus postpartum were 1.05 (0.92-1.19) for AUC0-24h and 1.00 (0.83-1.21) for Cmax. The median (range) ratio of abacavir cord plasma to maternal plasma was 1.0 (0.7-1.0, n = 3). Viral load at the third trimester visit was less than 50 copies/ml in 13 participants (93%; one unknown). In total, 13 (93%; one unknown) children were tested HIV-negative.
  
  
  
  The pharmacokinetics of abacavir 600 mg q.d. during pregnancy are equivalent to postpartum. No dose adjustments are required during pregnancy and similar antiviral activity is expected.
authors.affiliation: aDepartment of Pharmacy, Radboud Institute of Health Sciences bDepartment of Pharmacology and Toxicology, Radboud Institute of Molecular Life Sciences, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands cInfectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium dDepartment of Obstetrics; Charité Universitätsmedizin, Berlin, Germany eHIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona fHospital Universitario Virgen de las Nieves Granada, Granada, Spain gChelsea & Westminster Hospital hImperial College Healthcare NHS Trust iNorth Middlesex Hospital London, London, UK jErasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Stein
authors.initials: S
authors.lastname: Schalkwijk
authors.forename: Angela
authors.initials: A
authors.lastname: Colbers
authors.forename: Deborah
authors.initials: D
authors.lastname: Konopnicki
authors.forename: Katharina
authors.initials: K
authors.lastname: Weizsäcker
authors.forename: José
authors.initials: J
authors.lastname: Moltó
authors.forename: Carmen Hidalgo
authors.initials: CH
authors.lastname: Tenorio
authors.forename: David
authors.initials: D
authors.lastname: Hawkins
authors.forename: Graham
authors.initials: G
authors.lastname: Taylor
authors.forename: Chris
authors.initials: C
authors.lastname: Wood
authors.forename: Marchina
authors.initials: M
authors.lastname: van der Ende
authors.forename: David
authors.initials: D
authors.lastname: Burger
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D000099227:Abacavir